Navigation Links
EPIX Pharmaceuticals Announces Statistically Significant Results in,Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug,Candidate

actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that product candidates, including PRX-07034, may fail in the clinic or may not be successfully marketed or manufactured; risks relating to the our ability to advance the development of product candidates currently in the pipeline or in clinical trials, any failure to comply with regulations relating to our products and product candidates, including FDA requirements; failure to obtain the financial resources to complete development of product candidates; the risk that the FDA may interpret the results of our studies differently than we have; competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; the possibility of delays in the research and development necessary to select drug development candidates; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

Contact

EPIX
Kim C. Drapkin, 781-761-7602
Chief Financial Officer
or
Pure Communications
Andrea L. Johnston, 910-616-5858


'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global Business ... Trust Company (DTC) has made their final decision ... on the Company,s stock effective December 15, 2014, ... stock for depository and book entry transfer services. All ... is now once again fully "DTC Eligible", and ...
(Date:12/17/2014)... Dec. 17, 2014  Beamz Interactive, Inc. (OTCQB: ... products, today announced that it has signed an ... and supplier of innovative prosthetic, orthotic and assistive ... of the agreement, RSL Steeper will promote and ... configured for use within UK residential care facilities ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... SAN DIEGO, June 16, 2011 Neurocrine Biosciences, Inc. ... elagolix presentations have been accepted for the scientific program ... September 4-7, 2011 in Montpellier, France. This important meeting ... every three years, bringing together clinicians and basic scientists ...
... 2011 Cebix Incorporated announced today it ... for the treatment of complications of diabetes. The biopharmaceutical ... evaluate Ersatta™, its proprietary long-acting form of C-peptide, in ... disease, lack this endogenous peptide.  Following the successful completion ...
Cached Medicine Technology:Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 2Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 2Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 4
(Date:12/20/2014)... 2014 Recently, AngelWeddingDress.com has introduced its ... for the coming Christmas. In the promotion, all buyers ... , “We have something special for the women who ... season. Moreover, our new collections of 2015 dresses have ... now at greatly discounted prices. Visit our website now ...
(Date:12/20/2014)... The Twin Cities DI Day is ... the nation! Over 250 financial professionals come together each ... the industry, get motivated to protect their clients and ... and overcoming the challenges of disability. , On September ... came together to attend The 13th Annual Twin Cities ...
(Date:12/19/2014)... Today, Balfleet.com , a leading dress company ... dress promotion. All the old and new customers can ... Balfleet.com is well-known for its high quality trendy women’s ... dresses and more. Its formal dresses are quality made ... can create an elegant look when paired with any ...
(Date:12/19/2014)... 19, 2014 Sub Zero Ice Cream is ... blood drive Sunday the 28th from 2pm-6pm at the Expo ... Road in Sarasota, FL. , Inquiries regarding time slots and ... participating in the donating process, Sub Zero Ice Cream & ... custom ice cream. , About Sub Zero Ice Cream & ...
(Date:12/19/2014)... December 19, 2014 Silver Dollar City ... world record -- for the first time ever, Silver Dollar ... book, Guinness World Records 2015, listing the park’s wood coaster ... Coaster. In additional awards announced this week, Silver Dollar City ... Lights in the US,” USA Today’s 10Best awards for “Best ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2
... Singapore – The accomplishments of Thailand and Cambodia in ... been achieved primarily through the extensive use of condoms.// ... at Singapore's Ministry of Health, said "The 100 per ... two prominent examples of successful prevention efforts." ...
... have long been the cornerstones of managing type 2 ... these patients.// ,Now, a new systematic review shows ... the body’s sensitivity to insulin, and decreases blood lipids ... ,“Type 2 diabetes is an increasing problem in ...
... lay claim to the 'bird flu free nation' status next month, ... country for the last three months, federal Agriculture Minister Sharad Pawar ... avian influenza for the last three months, which makes us eligible ... ,The claim would be made before the World Organisation for ...
... a four-year project at 25 health care institutions around ... & Prevention// (CDC), implemented findings from successful clinical trials ... families. ,The purpose of the ICAI project ... & Immunology, the scientific journal of the American College ...
... the department of gynecology at the Catholic University of ... on the disease// endometriosis to identify its cause and ... results in the growth of the endometrial tissue outside ... are bleeding, pain, inflammation, adhesions and infertility. Statistics show ...
... in Malaysia have been forbidden to use Botox injections, for ... ,The National Fatwa Council issued the ban yesterday ... conditions such as cerebral palsy on the condition that it ... necessary for patients who do not have any other alternative., ...
Cached Medicine News:Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3Health News:Groundbreaking Asthma Intervention Lessons Help Inner-City Children 2
Karlin Lumbar Microdiscectomy Curette, length 9 1/2" (24.13 cm)....
PG Magnum Cup Curettes with large capacity cup sizes, total length 12.6" (32 cm) handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm)....
Karlin Cervical Microdiscectomy Curette, length 8 1/2" (21 cm)....
Microsect Curette with increased cutting edge and modified shaft, 10"....
Medicine Products: